+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human Papillomavirus Vaccine Market - Global Forecast 2026-2032- Product Image
Human Papillomavirus Vaccine Market - Global Forecast 2026-2032- Product Image
New

Human Papillomavirus Vaccine Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 184 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4858029
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The human papillomavirus vaccine market is rapidly adapting to evolving clinical protocols, policy shifts, and public health priorities. Senior leaders must respond decisively in a complex environment to deliver effective vaccination programs and optimize health outcomes.

Market Snapshot: Human Papillomavirus Vaccine Market

The global human papillomavirus vaccine market demonstrates robust momentum, expanding from USD 4.93 billion in 2025 to USD 5.27 billion in 2026, with a forecasted compound annual growth rate (CAGR) of 7.26%. By 2032, projections see the market reaching USD 8.05 billion. This positive trajectory follows increasing vaccine uptake, broad integration into national immunization programs, and active policy support. Stakeholders are broadening vaccine procurement efforts, adapting distribution practices, and enhancing program flexibility to sustain growth amid changing regulatory and operational contexts.

Scope & Segmentation

  • Vaccine Formulation: Covers nine-valent vaccines offering comprehensive coverage and adaptable bivalent or quadrivalent formulations, which align with varied program mandates and contractual requirements.
  • Care Settings: Targets clinical administration across hospitals, clinics, and public health facilities, each with specific delivery and procurement strategies suited for adolescent and adult patient groups.
  • Distribution Channels: Accounts for hospital and retail pharmacies as key outlets for public access, plus online channels that enhance convenience and privacy for recipients.
  • Age Cohorts: Encompasses strategies for adolescent vaccination, catch-up campaigns for older teens and young adults, and adult-focused approaches providing tailored immunization pathways.
  • Gender: Assesses vaccination across female and male populations to address global shifts toward gender-neutral protection and evolving public health guidelines.
  • Regions: Incorporates the Americas, Europe, Middle East, Africa, and Asia Pacific, each with its own infrastructure capabilities, policy environment, and procurement methods impacting vaccine rollout efficiency.
  • Technology: Explores the integration of advanced digital registries, virtual engagement solutions, and modernized cold chain logistics to support provider operations and enhance tracking of vaccine uptake.

Key Takeaways for Decision Makers

  • Recent guideline updates broaden age eligibility, driving the need for flexible provider and patient engagement models adapted to changing recommendations.
  • School-based and community engagement initiatives are central for accelerating vaccine adoption, particularly among underserved or high-risk groups.
  • Enhancements in supply chain strategy, including diversification of production and enhancements in distribution, help reduce operational risk, while certain regions still experience challenges due to resource and policy constraints.
  • Utilization of telehealth platforms and digital pharmacy networks expands community reach and patient engagement, supporting wider immunization coverage.
  • Equity-centered procurement approaches, integrating public and private incentives, contribute to more inclusive program outcomes and reduction of coverage disparities.
  • Collaborative contracting frameworks promote system resiliency by enabling prompt response to evolving demand, operational interruptions, or policy changes across the vaccine supply ecosystem.

Tariff Impact: Navigating US Policy Adjustments

Recent and anticipated tariff adjustments in the United States are influencing manufacturers and buyers dependent on international supply chains. These changes are encouraging a shift toward regional manufacturing capacity, updates to contract terms for cost management, and new procurement strategies. The evolving policy climate introduces additional challenges for smaller buyers and non-governmental organizations, underscoring the need for transparent supply mechanisms and targeted advocacy to support ongoing vaccine access for all stakeholders.

Methodology & Data Sources

This report utilizes a stringent multi-source methodology, drawing on expert interviews, regulatory analysis, and real-time supply chain evaluation. Scenario modeling and stress tests are applied to deliver actionable insights and executive-oriented guidance for decision-making in the human papillomavirus vaccine market.

Why This Report Matters

  • Presents a clear framework for anticipating market shifts tied to clinical standards, regulatory updates, and supply chain stability.
  • Supports manufacturers, healthcare providers, and payers in optimizing strategies for engagement, distribution resiliency, and population reach.
  • Facilitates precise allocation of capital and resources with intelligence into operational challenges and infrastructure potential across diverse settings.

Conclusion

Successful adoption of human papillomavirus vaccines depends on cohesive clinical, operational, and policy integration. Executives who align with evolving dynamics and stakeholder needs can drive measurable improvements in program impact and public health outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Human Papillomavirus Vaccine Market, by Vaccine Type
8.1. 9-Valent
8.2. Bivalent
8.3. Quadrivalent
9. Human Papillomavirus Vaccine Market, by Age Group
9.1. 15-26 Years
9.2. 27 Years And Above
9.3. 9-14 Years
10. Human Papillomavirus Vaccine Market, by Gender
10.1. Female
10.2. Male
11. Human Papillomavirus Vaccine Market, by End User
11.1. Clinics
11.2. Hospitals
11.3. Public Health Centers
12. Human Papillomavirus Vaccine Market, by Distribution Channel
12.1. Hospital Pharmacies
12.2. Online Pharmacies
12.3. Retail Pharmacies
13. Human Papillomavirus Vaccine Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Human Papillomavirus Vaccine Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Human Papillomavirus Vaccine Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Human Papillomavirus Vaccine Market
17. China Human Papillomavirus Vaccine Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AstraZeneca plc
18.6. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd
18.7. Bharat Biotech International Ltd
18.8. Biological E. Limited
18.9. CSPC Pharmaceutical Group Ltd
18.10. Dynavax Technologies Corporation
18.11. Emergent BioSolutions Inc.
18.12. GlaxoSmithKline plc
18.13. Johnson & Johnson Services, Inc.
18.14. Merck & Co., Inc.
18.15. Novavax, Inc.
18.16. Pfizer Inc.
18.17. Sanofi S.A.
18.18. Serum Institute of India Ltd
18.19. Shenzhen Kangtai Biological Products Co., Ltd
18.20. Sinovac Biotech Ltd
18.21. Walvax Biotechnology Co., Ltd
18.22. Xiamen Innovax Biotech Co., Ltd
18.23. Yuxi Zerun Biotechnology Co., Ltd
18.24. Zydus Lifesciences Ltd
List of Figures
FIGURE 1. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-VALENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-VALENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-VALENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 15-26 YEARS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 15-26 YEARS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 15-26 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 27 YEARS AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 27 YEARS AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 27 YEARS AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-14 YEARS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-14 YEARS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-14 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY FEMALE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY FEMALE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY MALE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY MALE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY MALE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 51. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 52. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 53. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 54. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 55. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 56. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 58. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 59. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 60. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 61. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 62. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 64. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 65. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 66. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 67. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 68. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 74. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 76. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 77. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 78. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 79. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 82. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 83. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 84. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 85. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 86. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 88. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 89. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 90. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 91. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 101. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 102. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 103. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 105. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 107. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 108. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 109. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 111. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 113. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 114. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 115. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 116. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 117. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 119. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 120. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 121. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 125. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 126. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 127. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 129. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 131. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 132. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 133. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 137. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 138. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 139. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 140. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 141. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 142. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 143. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 144. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 145. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 146. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 147. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Human Papillomavirus Vaccine market report include:
  • AstraZeneca plc
  • Beijing Wantai Biological Pharmacy Enterprise Co., Ltd
  • Bharat Biotech International Ltd
  • Biological E. Limited
  • CSPC Pharmaceutical Group Ltd
  • Dynavax Technologies Corporation
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Ltd
  • Shenzhen Kangtai Biological Products Co., Ltd
  • Sinovac Biotech Ltd
  • Walvax Biotechnology Co., Ltd
  • Xiamen Innovax Biotech Co., Ltd
  • Yuxi Zerun Biotechnology Co., Ltd
  • Zydus Lifesciences Ltd

Table Information

Report AttributeDetails
No. of Pages184
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.27 Billion
Forecasted Market Value ( USD ) by 2032 $ 8.05 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Human Papillomavirus Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 - Product Image

Human Papillomavirus Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

  • Report
  • 130 Pages
  • Global
From
Human Papillomavirus Vaccine Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Human Papillomavirus Vaccine Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 77 Pages
  • Global
From
Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Human Papillomavirus Vaccines Market Size, Share & Trends Analysis Report by Type (Bivalent, Quadrivalent, Nonavalent), Disease (Cervical Cancer, Anal Cancer), Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Human Papillomavirus Vaccines Market Size, Share & Trends Analysis Report by Type (Bivalent, Quadrivalent, Nonavalent), Disease (Cervical Cancer, Anal Cancer), Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 195 Pages
  • Global
From
Human Papillomavirus (HPV) Vaccines Market - Global Strategic Business Report - Product Image

Human Papillomavirus (HPV) Vaccines Market - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From

About the Market

The HPV Vaccine is a type of cancer vaccine used to prevent infection from the human papillomavirus (HPV). HPV is a virus that can cause cervical cancer, as well as other types of cancer. The HPV Vaccine is typically administered to adolescents and young adults, and is recommended by the World Health Organization (WHO) as part of routine immunization programs. The vaccine is available in both a bivalent and quadrivalent form, and is designed to protect against the two most common types of HPV that cause cervical cancer. The HPV Vaccine market is a rapidly growing segment of the cancer vaccine market. It is estimated that the global HPV Vaccine market will reach $4.5 billion by 2027, driven by increasing awareness of the virus and its associated health risks, as well as the availability of the vaccine in many countries. Some of the major companies in the HPV Vaccine market include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Pfizer, and CSL. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.